Aratana Therapeutics Inc (NASDAQ:PETX) Stake Reduced by Bank of Montreal Can

Bank of Montreal Can trimmed its holdings in shares of Aratana Therapeutics Inc (NASDAQ:PETX) by 10.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 46,046 shares of the biopharmaceutical company’s stock after selling 5,655 shares during the period. Bank of Montreal Can owned approximately 0.09% of Aratana Therapeutics worth $166,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Aratana Therapeutics by 3.8% in the third quarter. Vanguard Group Inc. now owns 2,044,208 shares of the biopharmaceutical company’s stock worth $11,938,000 after buying an additional 75,166 shares in the last quarter. Vanguard Group Inc raised its position in Aratana Therapeutics by 3.8% during the third quarter. Vanguard Group Inc now owns 2,044,208 shares of the biopharmaceutical company’s stock valued at $11,938,000 after purchasing an additional 75,166 shares in the last quarter. Rhumbline Advisers raised its position in Aratana Therapeutics by 49.2% during the fourth quarter. Rhumbline Advisers now owns 61,611 shares of the biopharmaceutical company’s stock valued at $378,000 after purchasing an additional 20,326 shares in the last quarter. State Board of Administration of Florida Retirement System grew its stake in shares of Aratana Therapeutics by 849.0% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 149,404 shares of the biopharmaceutical company’s stock valued at $916,000 after buying an additional 133,660 shares during the last quarter. Finally, Creative Planning bought a new position in shares of Aratana Therapeutics during the fourth quarter valued at about $127,000. Hedge funds and other institutional investors own 65.00% of the company’s stock.

PETX has been the topic of a number of recent research reports. TheStreet cut Aratana Therapeutics from a “c-” rating to a “d+” rating in a research note on Monday, March 4th. HC Wainwright cut Aratana Therapeutics from a “buy” rating to a “neutral” rating and set a $5.00 target price on the stock. in a research note on Friday, April 26th. Zacks Investment Research cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, March 14th. Finally, Credit Suisse Group cut Aratana Therapeutics from an “outperform” rating to a “neutral” rating and set a $4.76 target price on the stock. in a research note on Tuesday, April 30th. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $5.08.

Aratana Therapeutics stock traded down $0.07 during trading hours on Wednesday, hitting $5.16. 392,306 shares of the stock traded hands, compared to its average volume of 812,185. The business’s 50-day moving average price is $4.83. The stock has a market capitalization of $245.83 million, a P/E ratio of -16.13 and a beta of 1.39. Aratana Therapeutics Inc has a one year low of $3.30 and a one year high of $7.16.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.04). Aratana Therapeutics had a negative net margin of 33.47% and a negative return on equity of 12.99%. The firm had revenue of $7.36 million for the quarter, compared to the consensus estimate of $6.98 million. On average, research analysts predict that Aratana Therapeutics Inc will post -0.31 EPS for the current year.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States.

See Also: What is the Current Ratio?

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply